The Apex Times
Above the Noise
Business Wire
BusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex Times
Back to front
Moderna schedules “Science Day” investor event for June 25
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jun 17, 7:23 AM EDT

Moderna schedules “Science Day” investor event for June 25

The Cambridge, Massachusetts biotech said it will hold an Investor Event - Science Day at 9:00 a.m. Eastern on Thursday, June 25, 2026.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Moderna, Inc. said it will hold an Investor Event - Science Day on Thursday, June 25, 2026, with the session scheduled to begin at 9:00 a.m. Eastern time.

The company’s announcement, carried by Access Newswire via Yahoo Finance, did not outline in detail what specific scientific updates or programs will be covered. It said only that the event is designed for investors and framed it as a “Science Day,” a format typically used by biotech firms to explain underlying research, clinical progress, and platform capabilities.

For Moderna, the timing of the event matters because investor-focused technical updates can influence how markets interpret the company’s pipeline and technology beyond quarterly financial results. “Science Day” events are often used to connect R&D milestones to commercial expectations, and to provide management a structured setting to answer investor questions.

The announcement comes as Moderna continues to trade on the Nasdaq under the ticker MRNA. Investors will likely watch for any clarifications around development timelines, trial readouts, and manufacturing or regulatory plans, topics that firms frequently emphasize during scientific events, though Moderna’s brief posting did not specify which areas it will address.

Moderna, known for its messenger RNA, or mRNA, technology, has historically used investor events to communicate how its platform is applied across different therapeutic and vaccine programs. In plain terms, mRNA medicines instruct cells to produce a protein, allowing the immune system to recognize targets or enabling therapeutic protein production, depending on the program. Companies like Moderna often tie these scientific concepts back to trial endpoints and potential scale-up pathways.

Still, based on the information disclosed in the post announcing the event, there is limited visibility into the agenda, the specific presentations, whether there will be a live webcast, and which internal leaders will appear. The announcement also did not state whether Moderna plans to release accompanying investor materials in advance or immediately after the event.

Next, investors and analysts will likely focus on what Moderna chooses to emphasize during the June 25 session, including any pipeline updates or experimental findings, and whether management provides new guidance or commentary that changes expectations for near-term milestones. Until more details are published, the practical takeaway is that Moderna has set a dedicated date and time for a science-focused investor forum, with substantive content to be disclosed closer to the event.

Why It Matters

  • Investor “Science Day” events can shape market perception by translating technical work into a clear pipeline narrative.
  • The scheduled date provides a near-term catalyst for renewed analyst focus and questions around Moderna’s programs.
  • What Moderna does or does not disclose during the event may affect expectations for upcoming clinical and commercial developments.
  • Investors will likely use the session to assess management’s framing of the science behind the company’s mRNA platform.

Sources

Key Facts

  • Moderna announced it will host an Investor Event titled “Science Day.”
  • The event is scheduled for Thursday, June 25, 2026.
  • Start time is 9:00 a.m. Eastern time.
  • The announcement was distributed via Access Newswire and published by Yahoo Finance.
  • Moderna trades on Nasdaq under the ticker MRNA.

Healthcare Related

Moderna schedules “Science Day” investor event for June 25 | The Apex Times